A Batch of Cefazolin Syringes and an Expired Hood Certification
The compounding pharmacist at a hospital-based outpatient pharmacy is on leave, and a certified technician with three years of sterile compounding experience is scheduled to prepare a 30-syringe batch of cefazolin 2 g in 0.9% sodium chloride for a home-infusion service. The biological safety cabinet was last certified on March 6; today is September 18. The pharmacy's own policy says cabinets are certified annually. The technician plans to use a single-dose vial that was punctured four days ago and stored in the refrigerator, and to label the syringes with a 30-day beyond-use date at room temperature. The cleanroom's most recent surface sampling was negative. When the covering pharmacist questions the plan, the technician says a previous employer ran the same batch size with the same dating and "never had a problem." The infusion service has four patients scheduled tomorrow, and the alternate supplier quotes a two-week lead time.
1. May the pharmacy compound this batch today? Walk through each element of the plan.
Read the worked answer
No. Three independent failures block this batch.
- The primary engineering control is out of certification. USP <797> requires the ISO Class 5 primary engineering control and the buffer area to be certified by an approved certifier at intervals of no more than six months, and again after relocation, repair, or significant change. Last certification March 6 with today September 18 is more than six months. The pharmacy's "annual" policy is simply noncompliant, and a negative surface sample does not substitute for certification - it is a snapshot, not a state-of-control determination.
- The vial is out of date for use. A single-dose vial punctured four days earlier cannot be used as a sterile source for a batch; single-dose vials have short in-use limits even inside a compliant ISO 5 environment, and refrigeration does not extend them to four days.
- The beyond-use date is unsupportable. A 30-day room-temperature BUD for a syringe of cefazolin is not within any recognized BUD category for this preparation. BUDs must be assigned from an established framework (or a validated stability study), not from "a previous employer did it this way."
Additionally, batch preparation requires pharmacist supervision and a documented master formulation record; the technician's three years of experience does not authorize independent compounding. The correct answer is to stop, not to negotiate the batch down to a smaller size.
2. CSPs prepared in the affected period have already been dispensed. What must the pharmacist-in-charge do?
Read the worked answer
Treat this as a look-back and risk assessment, not a documentation cleanup.
- Define the period. Identify every date since the certification lapsed on which CSPs were prepared in that environment, and every CSP still in inventory. Quarantine the remaining inventory; do not dispense it.
- Assess the failure mode. The risk from an uncertified environment is loss of sterility assurance (particles and microbial ingress), not chemical instability. That drives an assessment of which patients may have received a contaminated dose and whether any adverse events - fevers, line infections, phlebitis - have been reported.
- Notify. Inform the prescribers and the infusion service, notify patients as the organization's disclosure policy and Nebraska requirements direct, and document the notification. If sterility is genuinely in question, a recall and adverse-event reporting are the conservative and defensible course.
- Preserve records. Retain the compounding records, certification history, and sampling results; they will be requested by the Board or accreditor.
The instinct to protect the infusion schedule is exactly the wrong instinct: the exposure from a contaminated batch is far larger than a one-week delay.
3. What must be corrected before sterile compounding resumes, and how should the four scheduled patients be served in the interim?
Read the worked answer
Before resuming:
- Obtain certification of the primary engineering control and buffer area by an approved certifier; schedule it immediately and document the certificate.
- Rewrite the policy to a six-month certification interval with a tracking calendar that triggers scheduling 30 days ahead, and assign a named person to verify certificates on receipt.
- Rework the BUD table so every preparation is assigned to a recognized category or a validated study, and require a pharmacist to approve BUDs on the master formulation record.
- Retrain on single-dose vial in-use limits and on the prohibition on batching without pharmacist oversight. Address the technician's "previous employer" justification directly - experience with a noncompliant practice is not evidence of compliance.
Interim supply for the four patients: purchase commercially available premixed cefazolin product if clinically appropriate, obtain the doses from an appropriately registered 503B outsourcing facility (verify its current registration and the product's BUD), arrange preparation at a compliant site within the health system, or reschedule the infusion after the prescriber assesses urgency. Each option should be documented, including the prescriber's agreement. Compounding "just this once" while awaiting certification defeats the entire control and is the kind of decision a Board will examine line by line.